Molecular decodification of Gymnemic acid (cas 1399-64-0)s from Gymnema sylvestre. Discovery of a new class of liver X receptor antagonists

Add time:09/06/2019    Source:sciencedirect.com

The individual chemical components of commercial extract of Gymnema sylvestre, a medicinal plant used in the traditional systems of the Indian medicine for its antidiabetic and hypolipidemic properties, were isolated and evaluated for their capability to act as modulators of nuclear and membrane receptors involved in glucose and lipid homeostasis.The study disclosed for the first time that individual gymnemic acids are potent and selective antagonists for the β isoform of LXR. Indeed the above activity was shared by the most abundant aglycone gymnemagenin (10) whereas gymnestrogenin (11) was endowed with a dual LXRα/β antagonistic profile. Deep pharmacological investigation demonstrated that gymnestrogenin, reducing the expression of SREBP1c and ABCA1 in vitro, is able to decrease lipid accumulation in HepG2 cells. The results of this study substantiate the use of G. sylvestre extract in LXR mediated dislypidemic diseases.

We also recommend Trading Suppliers and Manufacturers of Gymnemic acid (cas 1399-64-0). Pls Click Website Link as below: cas 1399-64-0 suppliers

Prev:Document headingPharmacological and analytical aspects of Gymnemic acid (cas 1399-64-0): a concise report
Next:Original ResearchGTF-231, a Mixture of Gymnemic acid (cas 1399-64-0), Trigonelline and Ferulic Acid Significantly Ameliorates Oxidative Stress in Experimental Type 2 Diabetes in Rats)